Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIRE-11: intermittent versus continuous cetuximab + FOLFIRI first-line treatment in RAS/BRAF-wild-type metastatic colorectal cancer
2025-522377-12-00Phase 3Authorised
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Nov 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cetuximab, irinotecan, fluorouracil and folinic acid in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: Time to Failure of Strategy. Planned start Nov 2025; status: authorised.
02
Drugs
cetuximabirinotecanfluorouracilfolinic acid
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2025-522377-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522377-12-00.